Lilly Partners With Ascidian to Edit RNA for Kidney Disease Drugs

Lilly has secured exclusive rights to use Ascidian’s RNA exon‑editing platform for new kidney disease treatments. The system can fix faulty genes without permanently changing a patient’s DNA, offering an alternative to traditional CRISPR methods.

Deal Structure

• Upfront Payment: Ascidian receives a portion of the total $1.9 billion.
• Future Milestones: Remaining payments tied to development milestones, regulatory approvals, and sales.

Roles & Responsibilities

• Lilly: Takes over later stages—research, production, and market launch.
• Ascidian: Continues early studies and maintains other kidney projects.

Context in Genetic Medicine

• Lilly’s recent investments include a $1.13 billion purchase of Verve Therapeutics and collaborations with AI‑driven biotech firms.
• The partnership aims to reduce the burden of inherited kidney disorders by combining Ascidian’s technology with Lilly’s drug‑development expertise.

Technology Highlights

• RNA‑Based Approach: Shares benefits with CRISPR but avoids permanent DNA edits.
• Goal: Deliver safer, more precise therapies for kidney disease patients.